טוען...
Crbn(I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective treatments for multiple myeloma and myelodysplastic syndrome with del(5q). These molecules lack activity in murine models, limiting investigation of their therapeutic activity or toxicity in vivo. Here, we repor...
שמור ב:
| הוצא לאור ב: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6172563/ https://ncbi.nlm.nih.gov/pubmed/30064974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-05-852798 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|